{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignancies&page=46",
    "query": {
      "condition": "Malignancies",
      "page": 46
    },
    "page_size": 10
  },
  "pagination": {
    "page": 46,
    "page_size": 10,
    "total_count": 50362,
    "total_pages": 5037,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignancies&page=47&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Malignancies&page=45&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T03:18:50.686Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT07539155",
      "title": "Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancreatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Borderline Resectable/Unresectable Pancreatic Cancer",
        "Non Metastatic Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Intratumoral MMR Injection",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Arkansas",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2026-06-26",
      "completion_date": "2028-08",
      "has_results": false,
      "last_update_posted_date": "2026-09-01",
      "last_synced_at": "2026-10-31T03:18:50.686Z",
      "location_count": 1,
      "location_summary": "Little Rock, Arkansas",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07539155"
    },
    {
      "nct_id": "NCT01497626",
      "title": "Lapatinib and Bortezomib in Patients With Advanced Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Lapatinib and bortezomib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Georgetown University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2011-09",
      "completion_date": "2015-12",
      "has_results": false,
      "last_update_posted_date": "2016-02-17",
      "last_synced_at": "2026-10-31T03:18:50.686Z",
      "location_count": 1,
      "location_summary": "Washington D.C., District of Columbia",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01497626"
    },
    {
      "nct_id": "NCT06171178",
      "title": "A Study of ASP1012 in Adults With Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "ASP1012",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2024-05-15",
      "completion_date": "2025-09-11",
      "has_results": false,
      "last_update_posted_date": "2026-08-27",
      "last_synced_at": "2026-10-31T03:18:50.686Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Newport Beach, California • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06171178"
    },
    {
      "nct_id": "NCT00582985",
      "title": "Open Label Phase 1 Dose Finding Study of TRC105 in Patients With Solid Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cancer",
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "TRC105 chimeric anti-CD105 antibody",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tracon Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 51,
      "start_date": "2007-12",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2012-03-05",
      "last_synced_at": "2026-10-31T03:18:50.686Z",
      "location_count": 4,
      "location_summary": "Scottsdale, Arizona • Santa Monica, California • Buffalo, New York + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00582985"
    },
    {
      "nct_id": "NCT04064515",
      "title": "CTCs in Cervix Cancer",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cervical Cancer",
        "HPV"
      ],
      "interventions": [
        {
          "name": "Blood Assayed for CTCs",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 100 Years · Female only"
      },
      "enrollment_count": 4,
      "start_date": "2020-03-02",
      "completion_date": "2020-04-23",
      "has_results": false,
      "last_update_posted_date": "2022-08-05",
      "last_synced_at": "2026-10-31T03:18:50.686Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04064515"
    },
    {
      "nct_id": "NCT02715843",
      "title": "Extended Treatment Access Study of MT-3724 for Subjects With Relapsed Non-Hodgkin's B-Cell Lymphoma",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Non-Hodgkin's B-cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "MT-3724",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Molecular Templates, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2019-10-11",
      "last_synced_at": "2026-10-31T03:18:50.686Z",
      "location_count": 3,
      "location_summary": "Tucson, Arizona • New York, New York • Houston, Texas",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02715843"
    },
    {
      "nct_id": "NCT01438476",
      "title": "Postoperative Thoracic Epidural Analgesia Versus Intravenous Patient-Controlled Analgesia For Liver and/or Pancreas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Liver Cancer",
        "Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "Intravenous Patient-Controlled Analgesia (IVPCA)",
          "type": "PROCEDURE"
        },
        {
          "name": "Thoracic Epidural Analgesia (TEA)",
          "type": "PROCEDURE"
        },
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Pain Assessment",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BEHAVIORAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 178,
      "start_date": "2012-01-26",
      "completion_date": "2017-10-18",
      "has_results": true,
      "last_update_posted_date": "2020-02-12",
      "last_synced_at": "2026-10-31T03:18:50.686Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01438476"
    },
    {
      "nct_id": "NCT03564340",
      "title": "Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Ovarian Cancer",
        "Recurrent Fallopian Tube Cancer",
        "Recurrent Primary Peritoneal Cancer",
        "Recurrent Endometrial Cancer",
        "Endometrial Cancer",
        "Low-grade Serous Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "Ubamatamab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 890,
      "start_date": "2018-05-21",
      "completion_date": "2027-05-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-31T03:18:50.686Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03564340"
    },
    {
      "nct_id": "NCT00074750",
      "title": "Study of DT388GMCSF Fusion Protein in Acute Myelogenous Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Chronic Myelomonocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "DTGM",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2003-12",
      "completion_date": "2004-12",
      "has_results": false,
      "last_update_posted_date": "2012-02-22",
      "last_synced_at": "2026-10-31T03:18:50.686Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00074750"
    },
    {
      "nct_id": "NCT00062374",
      "title": "Irinotecan and Cisplatin in Treating Patients Who Are Undergoing Surgery For Locally Advanced Cancer of the Stomach or Gastroesophageal Junction",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gastric Adenocarcinoma",
        "Stage II Gastric Cancer",
        "Stage III Gastric Cancer",
        "Stage IV Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Fludeoxyglucose F-18",
          "type": "RADIATION"
        },
        {
          "name": "Fluorothymidine F-18",
          "type": "OTHER"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Therapeutic Conventional Surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2003-06",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2017-07-06",
      "last_synced_at": "2026-10-31T03:18:50.686Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00062374"
    }
  ]
}